Transforming the discovery of novel GPCR-targeted therapies
The Himalayas are the result of an ongoing, 50 million year-long collision between the Indian and Eurasian Tectonic Plates. As tectonic movements on the Earth’s surface affect the planet, GPCR interactions represent surface events that have profound effects on cell responses.
About Us
President and CEO, Director
Chief Operating Officer,
Chief Financial Officer
Anthony Muslin, M.D.
Chief Development Officer
Anthony Muslin, M.D.
Chief Development Officer
Marc Schwabish, Ph.D.
Marc Schwabish, Ph.D.
Chief Medical Officer
Peter McNamara, Ph.D.
Chief Scientific Officer
Timothy A. Springer, Ph.D.
Our Science
G protein-coupled receptors (GPCRs) are central to human biology and are the target of ~1/3 of all approved drugs. GPCRs remain a large untapped opportunity as many receptors remain unexplored or are undruggable by small molecules. A biologic approach will address major challenges by increasing specificity and by facilitating the targeting of GPCRs whose natural ligands are peptides or proteins.
Tectonic has unparalleled expertise in the biochemistry and biophysics of GPCRs, and the knowledge and experience to translate basic research in this field into novel therapies. Our GEODe™ platform overcomes the challenges encountered to date in GPCR biologic discovery campaigns, enabling the advancement of novel GPCR-targeting therapies.
News & Media
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
March 26, 2024
Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies. TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and topline Phase 1B data expected in 2025.
Tectonic Therapeutic Announces Participation at Investor Conferences in March
February 27, 2024
Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March.
January 30, 2024
AVROBIO and Tectonic Therapeutic Announce Merger
January 30, 2024
Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins
November 28, 2023
Tectonic Therapeutic, Inc. a biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), today announced it completed dosing of the first human cohort in its Fc-relaxin fusion program targeting the RXFP1 receptor.
July 19, 2022
Fierce Biotech names Tectonic Therapeutic as one of its “Fierce 15” Biotech Companies of 2021
September 27, 2021
Tectonic Therapeutic today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
September 22, 2021
Tectonic Therapeutic, a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has been named as one of the Endpoints 11 most promising private startups in biotech.
April 15, 2021
Tectonic Therapeutic, a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has raised $80 million in a Series A financing.
Congratulations to the Winners of the 2020 Harvard President’s Innovation Challenge
Careers
Scientist – Assay Development and Biochemical Screening
(Sr) Research Associate – Antibody Discovery
(Sr) Research Associate / Scientist I – Cell Culture and Membrane Protein Expression
At Tectonic we are motivated by a “speak-up culture” where divergent perspectives are shared openly, respectfully, and fearlessly. We understand that we can learn from both triumphs and setbacks and that breakthroughs are often the result of the most unexpected insights.
We believe a shared commitment to excellence and creativity is what makes meaningful scientific and medical advances possible. We work hard yet find time to laugh together as we drive toward achieving a common goal-improving human health. We collaborate because we recognize the urgent need for new therapies and that teams score more goals than individuals. We value diversity both in who we are and in how we think because the more perspectives we bring to a challenge, the more likely we are to succeed.
Tectonic – a place to grow and succeed together.
Contact Us
490 Arsenal Way, Suite 210
Watertown, MA 02472
info@tectonictx.com
Copyright © 2024 Tectonic Therapeutic
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.